Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Glaxo's Win in Case Against Teva Lifts Other Drugmakers - Bloomberg
US states accuse Teva and other drugmakers of colluding to inflate prices over 1,000%
Watch Mylan Board Rejects $40.1B Teva Takeover Bid - Bloomberg
Teva Abandons Search to Make Covid-19 Vaccine for Partners - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva (TEVA) Agrees to $225 Million Texas Opioid Settlement, AG Says - Bloomberg
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva Agrees to Stop Selling Amgen Generic Following Patent Infringement Settlement | Ctech
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva shares drop 18%, lose third of their value in two days - Business - Haaretz.com
Teva Pharmaceutical CEO on Bringing His Company Back from the Brink | Barron's
Israel Not Aiming to Punish Teva on Job Cuts, Official Says - Bloomberg
Amid sales slump, Teva CEO Schultz's pay falls 7% to $14.7M | Fierce Pharma
Watch How to Trade Teva Pharmaceutical - Bloomberg
Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg
Teva Gets Generic Drugmakers' Backing in Bid to Redo Label Case - Bloomberg Law
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Glaxo/Teva Ruling Could Spell Trouble for Generic Drugmakers
Teva Pharmaceuticals (TEVA) Stock Gets Upgraded at HSBC - TheStreet
Teva to Cut Up to 25% of Israel Workforce, Calcalist Says - Bloomberg
Kare Schultz, president and chief executive officer of Teva... News Photo - Getty Images
Watch Teva Makes Mylan Bid for $82 per Share - Bloomberg
Teva's $225 Million Opioid Deal With Texas Is Its Biggest (2)
